Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients.

Blood Reviews
Wobke E M van DijkRolf T Urbanus

Abstract

Thrombopoietin receptor agonist (TPO-RA) treatment increases the thrombosis rate in immune thrombocytopenia (ITP). We hypothesize that TPO-RAs influence platelet function, global and secondary hemostasis and/or fibrinolysis. A systematic review was performed. If possible, data were compared between responders (relevant increase in platelet count), and non-responders. Twelve observational studies with 305 patients were included (responders (127/150 (85%))). There were indications that TPO-RA treatment enhanced platelet function, with respect to platelet-monocyte aggregates, soluble P-selectin, GPVI expression, and adhesion under flow. Studies addressing global and secondary hemostasis and fibrinolysis were scarce. Overall, no changes were found during TPO-RA treatment, apart from an accelerated clot formation and conflicting data on levels of plasminogen activator inhibitor (PAI)-1. The parameters that increased have previously been associated with thrombosis in other patient groups, and might contribute to the increased rate of thrombosis observed in TPO-RA-treated ITP patients.

References

May 15, 1996·The Biochemical Journal·B Rodríguez-Liñares, S P Watson
Feb 14, 1998·Journal of the American College of Cardiology·M I FurmanA D Michelson
Nov 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·P AndréD D Wagner
Apr 12, 2002·Biochemical and Biophysical Research Communications·Heather E TibblesFatih M Uckun
Jan 8, 2003·The Journal of Experimental Medicine·Steffen MassbergBernhard Nieswandt
Mar 22, 2003·Blood·Bernhard Nieswandt, Steve P Watson
Apr 29, 2003·British Journal of Haematology·Erim Van OsGijsbert Van Willigen
Apr 29, 2006·British Journal of Haematology·McDonald K HorneElizabeth K Hoddeson
May 5, 2006·Seminars in Thrombosis and Hemostasis·Jan Willm N Akkerman
Jul 27, 2006·JAMA : the Journal of the American Medical Association·Gregor HronPaul A Kyrle
Aug 26, 2006·Pediatric Blood & Cancer·Simon PanzerIngrid Pabinger
Oct 5, 2006·Endocrine, Metabolic & Immune Disorders Drug Targets·A TesseR Andriantsitohaina
Oct 20, 2006·The New England Journal of Medicine·James B BusselJanet L Nichol
Feb 10, 2007·Blood·David J Kuter
Mar 1, 2007·Blood·Julian M JenkinsConnie L Erickson-Miller
Mar 10, 2007·Blood·Olga PanesDiego Mezzano
Jun 15, 2007·Thrombosis Research·Armando TripodiPier Mannuccio Mannucci
Jul 28, 2007·European Journal of Haematology·Simon PanzerIngrid Pabinger
Mar 20, 2008·JAMA : the Journal of the American Medical Association·Irene D BezemerFrits R Rosendaal
Mar 28, 2008·Journal of Thrombosis and Haemostasis : JTH·L BidotY S Ahn
Aug 30, 2008·The New England Journal of Medicine·Bruce Furie, Barbara C Furie
Oct 25, 2008·Clinical Chemistry·Sabine EichingerPaul A Kyrle
Apr 29, 2009·Angiology·Jonathan SmoutGererd Stansby
Feb 13, 2010·British Journal of Haematology·Elizabeth E GardinerRoss I Baker
Jul 24, 2010·International Journal of Hematology·Cheryl EngerAndrew T McAfee

❮ Previous
Next ❯

Citations

Apr 7, 2021·British Journal of Haematology·Dawn SwanJecko Thachil

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Coagulation Signaling Pathways

Coagulation is the process by which a blood clot is formed. This process includes both the formation of a platelet plug as well as a cascade of clotting factors resulting in the formation of fibrin strands. Find the latest research on coagulation signaling pathways here.